To assess whether this specific MAVS degradation is not a consequence of a feedback loop mediated by the production of type I IFN, cells were either treated with IFN-α2 or IFN-β, or treated after infection with a neutralizing antibody raised against IFNAR1, a chain of the IFN-α/β receptor. This evidence concerns the gene IFNA1 and infection.